Top

Published in:

Open Access 01-12-2013 | Research

Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure

Authors: Kiriaki Panagopoulos, Sam Cross-Knorr, Christen Dillard, Dionysios Pantazatos, Michael Del Tatto, David Mills, Lisa Goldstein, Joseph Renzulli, Peter Quesenberry, Devasis Chatterjee

Published in: Molecular Cancer | Issue 1/2013

Abstract

Background

Extracellular vesicle (EV) trafficking is a fundamental cellular process that occurs in cells and is required for different aspects of pathophysiology. EV trafficking leads to changes in cellular function including apoptosis, angiogenesis and proliferation required for increased tumor formation.

Results

We report several phenotypic changes mediated by EVs isolated from non-malignant and malignant prostate cells as well as patient biopsied prostate tumor samples. EVs can reverse the resistance of prostate cancer cells to camptothecin EVs isolated from non-malignant PrECs (Prostate Epithelial Cells) can reverse soft agar colony formation of malignant DU145 cells, with the reciprocal effect observed. Isolation of EVs from 2 Gleason grade 8 prostate cancer patients significantly induced soft agar colony formation of non-malignant PrECs. We have identified proteins via antibody and Mass spectrometry analysis that may be responsible for the phenotypic changes. Mass spectrometry analysis of protein lysates using ProteoIQ revealed protein candidates associated with gene ontology annotations that may be responsible for this phenotypic change. Ingenuity Pathway Analysis was used to identify statistically relevant canonical pathways and functions associated the protein IDs and expression values obtained using ProteoIQ. Western blot analysis confirmed the increase of 14-3-3 zeta, pRKIP and prohibitin protein levels in PrEC cells co-cultured with patient EVs. 14-3-3 proteins were also found as common proteins of 3 other Gleason grade 8 patients.

Conclusion

Our study provides a rational basis to further investigate putative proteins, such as 14-3-3 and prohibitin and genetic factors that may be responsible for phenotypic changes that are associated with prostate cancer progression.

Available only for authorised users

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003, 169: 517-523. 10.1016/S0022-5347(05)63946-8CrossRefPubMed

Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002, 360: 103-106. 10.1016/S0140-6736(02)09408-4CrossRefPubMed

Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92–02. J Clin Oncol. 2003, 21: 3972-3978. 10.1200/JCO.2003.11.023CrossRefPubMed

Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005, 61: 1285-1290. 10.1016/j.ijrobp.2004.08.047CrossRefPubMed

Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001, 50: 1243-1252. 10.1016/S0360-3016(01)01579-6CrossRefPubMed

Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS: The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006, 66: 794-802. 10.1158/0008-5472.CAN-05-1716CrossRefPubMed

Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, Roninson IB: Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci USA. 2000, 97: 4291-4296. 10.1073/pnas.97.8.4291PubMedCentralCrossRefPubMed

Currid CA, O’Connor DP, Chang BD, Gebus C, Harris N, Dawson KA, Dunn MJ, Pennington SR, Roninson IB, Gallagher WM: Proteomic analysis of factors released from p21-overexpressing tumour cells. Proteomics. 2006, 6: 3739-3753. 10.1002/pmic.200500787CrossRefPubMed

Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J: Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA. 2001, 98: 12072-12077. 10.1073/pnas.211053698PubMedCentralCrossRefPubMed

10.

Shay JW, Roninson IB: Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004, 23: 2919-2933. 10.1038/sj.onc.1207518CrossRefPubMed

11.

Keller S, Sanderson MP, Stoeck A, Altevogt P: Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006, 107: 102-108. 10.1016/j.imlet.2006.09.005CrossRefPubMed

12.

Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP: Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005, 35: 169-173. 10.1016/j.bcmd.2005.07.001CrossRefPubMed

13.

Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C: Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010, 123: 1603-1611. 10.1242/jcs.064386PubMedCentralCrossRefPubMed

14.

Taylor DD, Gercel-Taylor C: Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005, 92: 305-311.PubMedCentralPubMed

15.

Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L: Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66: 9290-9298. 10.1158/0008-5472.CAN-06-1819CrossRefPubMed

16.

Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009, 69: 5601-5609. 10.1158/0008-5472.CAN-08-3860PubMedCentralCrossRefPubMed

17.

Sandvig K, Llorente A: Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Mol Cell Proteomics. 2012, 11: M111-012914PubMedCentralCrossRefPubMed

18.

Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB: RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem. 2004, 279: 17515-17523. 10.1074/jbc.M313816200CrossRefPubMed

19.

Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M: Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004, 64: 8867-8875. 10.1158/0008-5472.CAN-04-2938CrossRefPubMed

20.

Renzulli JF, Del Tatto M, Dooner G, Aliotta J, Goldstein L, Dooner M, Colvin G, Chatterjee D, Quesenberry P: Microvesicle induction of prostate specific gene expression in normal human bone marrow cells. J Urol. 2010, 184: 2165-2171. 10.1016/j.juro.2010.06.119PubMedCentralCrossRefPubMed

21.

Zhang H, Pelech S: Using protein microarrays to study phosphorylation-mediated signal transduction. Semin Cell Dev Biol. 2012, 23: 872-882. 10.1016/j.semcdb.2012.05.009CrossRefPubMed

22.

Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T: Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J. 2012, 2: e60- 10.1038/bcj.2012.5PubMedCentralCrossRefPubMed

23.

Mahon KL, Henshall SM, Sutherland RL, Horvath LG: Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer. 2011, 18: R103-R123. 10.1530/ERC-10-0343CrossRefPubMed

24.

Covey JM, Jaxel C, Kohn KW, Pommier Y: Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989, 49: 5016-5022.PubMed

25.

Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR: Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene. 2009, 28: 2796-2805. 10.1038/onc.2009.139PubMedCentralCrossRefPubMed

26.

Hermeking H: The 14-3-3 cancer connection. Nat Rev Cancer. 2003, 3: 931-943.CrossRefPubMed

27.

Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV: Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer. 2012, 131: 49-58. 10.1002/ijc.26327PubMedCentralCrossRefPubMed

28.

Gaiffe E, Pretet JL, Launay S, Jacquin E, Saunier M, Hetzel G, Oudet P, Mougin C: Apoptotic HPV positive cancer cells exhibit transforming properties. PLoS One. 2012, 7: e36766- 10.1371/journal.pone.0036766PubMedCentralCrossRefPubMed

29.

Barton BE, Karras JG, Murphy TF, Barton A, Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther. 2004, 3: 11-20. 10.1186/1476-4598-3-11CrossRefPubMed

30.

Bromberg J: Stat proteins and oncogenesis. J Clin Invest. 2002, 109: 1139-1142.PubMedCentralCrossRefPubMed

31.

Chatterjee D, Moen EL, Chin YE: Inhibition of STAT3 activation by RKIP in colon cancer. Forum on Immunopathological Diseases and Therapeutics. 2011, 2: 35-45. 10.1615/ForumImmunDisTher.v2.i1.50.CrossRef

32.

Fizazi K: The role of Src in prostate cancer. Ann Oncol. 2007, 18: 1765-1773. 10.1093/annonc/mdm086CrossRefPubMed

33.

Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie K, Wesseling S, Goumans MJ, Boer P, Joles JA, Braam B: IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol. 2010, 299: C354-362. 10.1152/ajpcell.00513.2009CrossRefPubMed

34.

Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM: STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res. 2012, 18: 127-139. 10.1158/1078-0432.CCR-11-1889PubMedCentralCrossRefPubMed

35.

Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR: Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003, 278: 13061-13068. 10.1074/jbc.M210015200CrossRefPubMed

36.

Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D: Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4. PLoS One. 2011, 6: e22456- 10.1371/journal.pone.0022456PubMedCentralCrossRefPubMed

37.

Wang S, Nath N, Fusaro G, Chellappan S: Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol. 1999, 19: 7447-7460.PubMedCentralCrossRefPubMed

38.

Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S: Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem. 2003, 278: 47853-47861. 10.1074/jbc.M305171200CrossRefPubMed

39.

Sievers C, Billig G, Gottschalk K, Rudel T: Prohibitins are required for cancer cell proliferation and adhesion. PLoS One. 2010, 5: e12735- 10.1371/journal.pone.0012735PubMedCentralCrossRefPubMed

40.

Radhakrishnan VM, Martinez JD: 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS One. 2010, 5: e11433- 10.1371/journal.pone.0011433PubMedCentralCrossRefPubMed

41.

Wang Z, Nesland JM, Suo Z, Trope CG, Holm R: The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3beta and epsilon are independent prognostic factors for these tumors. PLoS One. 2011, 6: e24843- 10.1371/journal.pone.0024843PubMedCentralCrossRefPubMed

42.

Pan Y, Zhong LJ, Zhou H, Wang X, Chen K, Yang HP, Xiaokaiti Y, Maimaiti A, Jiang L, Li XJ: Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis. Acta Pharmacol Sin. 2012, 33: 798-808. 10.1038/aps.2012.42PubMedCentralCrossRefPubMed

43.

Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D, Horie-Inoue K, Takahashi S, Ouchi Y, Homma Y, Inoue S: 14-3-3zeta, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res. 2012, 18: 5617-5627. 10.1158/1078-0432.CCR-12-0281CrossRefPubMed

44.

Titus MA, Tan JA, Gregory CW, Ford OH, Subramanian RR, Fu H, Wilson EM, Mohler JL, French FS: 14-3-3{eta} amplifies androgen receptor actions in prostate cancer. Clin Cancer Res. 2009, 15: 7571-7581. 10.1158/1078-0432.CCR-08-1976PubMedCentralCrossRefPubMed

45.

Urano T, Takahashi S, Suzuki T, Fujimura T, Fujita M, Kumagai J, Horie-Inoue K, Sasano H, Kitamura T, Ouchi Y, Inoue S: 14-3-3sigma is down-regulated in human prostate cancer. Biochem Biophys Res Commun. 2004, 319: 795-800. 10.1016/j.bbrc.2004.05.056CrossRefPubMed

46.

Lodygin D, Diebold J, Hermeking H: Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene. 2004, 23: 9034-9041. 10.1038/sj.onc.1208004CrossRefPubMed

47.

Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, Hancock JF: 14-3-3 facilitates Ras-dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol. 1998, 18: 3947-3955.PubMedCentralCrossRefPubMed

48.

Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R: Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science. 1994, 265: 1713-1716. 10.1126/science.8085158CrossRefPubMed

49.

Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R, Albert S, Rajalingam K, Hekman M, Rapp UR: Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins. J Biol Chem. 2009, 284: 3183-3194.CrossRefPubMed

Title: Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure
Authors: Kiriaki Panagopoulos
Sam Cross-Knorr
Christen Dillard
Dionysios Pantazatos
Michael Del Tatto
David Mills
Lisa Goldstein
Joseph Renzulli
Peter Quesenberry
Devasis Chatterjee
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-12-118

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells

Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme

6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells

Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells

The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis

The MicroRNA-148/152 Family: Multi-faceted Players

Keynote webinar | Spotlight on antibody–drug conjugates in cancer